GLPG0634 is a selective JAK1 inhibitor with IC50 of 10 nM, 28 nM, 810 nM, and 116 nM for JAK1, JAK2, JAK3, and TYK2, respectively.
*The following content is generated by AI and is for reference only.
Overview
GLPG0634 (also known as leronlimab) is a fully human monoclonal antibody targeting the CCR5 receptor, developed for immunomodulation. Molecular Formula: C71H112N20O22S2; CAS No.: Not publicly listed for commercial supply.
Application
- Oncology: Investigational use in solid tumor immunotherapy to enhance T-cell infiltration.
- Virology: Potential application in HIV treatment strategies by blocking viral entry mechanisms.
- Inflammatory Diseases: Research into autoimmune conditions requiring CCR5 pathway modulation.
Precautions
Strictly for clinical trials and R&D purposes only. Requires cold chain storage at 2-8°C. Handling must follow biosafety protocols due to biological origin and potential immunogenicity risks.